Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Blin

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|June 19, 2004
A longitudinal study of the evolution of cognitive function and affective state in patients with amyotrophic lateral sclerosisM Kilani, J Micallef, C Soubrouillard, et al.
British Journal of Clinical Pharmacology|March 22, 2001
Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteersG P Pageaux, J Micallef, M B Nataf, et al.
L'Encephale|April 3, 2019
F Gaillard-Bigot, X-Y Zendjidjian, F Kheloufi, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 1, 1997
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trialC M Beasley, S H Hamilton, A M Crawford, et al.
Clinical Neuropharmacology|April 1, 1996
A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosisO Blin, J P Azulay, C Desnuelle, et al.
Journal of the Neurological Sciences|August 1, 1994
Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophyO Blin, C Desnuelle, O Rascol, et al.
European Journal of Clinical Pharmacology|April 10, 2017
Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre?F Kheloufi, A Default, F Rouby, et al.
L'Encephale|February 27, 2017
[How may practitioners interpret the results of clinical trials?]J-M Azorin, M Adida, O Blin, et al.
Annals of Neurology|June 9, 1999
ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's diseaseO Rascol, O Blin, C Thalamas, et al.
Psychopharmacology|August 9, 2021
Functional connectivity and cognitive changes after donepezil treatment in healthy participantsP Péran, A S Salabert, T Dondaine, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|June 19, 2004
A longitudinal study of the evolution of cognitive function and affective state in patients with amyotrophic lateral sclerosisM Kilani, J Micallef, C Soubrouillard, et al.
British Journal of Clinical Pharmacology|March 22, 2001
Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteersG P Pageaux, J Micallef, M B Nataf, et al.
L'Encephale|April 3, 2019
F Gaillard-Bigot, X-Y Zendjidjian, F Kheloufi, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 1, 1997
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trialC M Beasley, S H Hamilton, A M Crawford, et al.
Clinical Neuropharmacology|April 1, 1996
A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosisO Blin, J P Azulay, C Desnuelle, et al.
Journal of the Neurological Sciences|August 1, 1994
Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophyO Blin, C Desnuelle, O Rascol, et al.
European Journal of Clinical Pharmacology|April 10, 2017
Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre?F Kheloufi, A Default, F Rouby, et al.
L'Encephale|February 27, 2017
[How may practitioners interpret the results of clinical trials?]J-M Azorin, M Adida, O Blin, et al.
Annals of Neurology|June 9, 1999
ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's diseaseO Rascol, O Blin, C Thalamas, et al.
Psychopharmacology|August 9, 2021
Functional connectivity and cognitive changes after donepezil treatment in healthy participantsP Péran, A S Salabert, T Dondaine, et al.
Pageof 15